Authors


Ben Kong, PharmD, BCPS

Latest:

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

Ben Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.







Christina Wu, MD

Latest:

Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer

Investigators discuss the use of targeted therapies to treat metastatic colorectal cancer.


Natalie A. Lockney, MD

Latest:

Advancing Pancreatic Cancer Care Through Intraoperative Radiation Therapy

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.


Christina S. Wu, MB, BCh, MD

Latest:

Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC

The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.


Rajat Thawani, MBBS

Latest:

Face-Off: Award Presentation Ceremony

Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.


Zizhen Feng, MD

Latest:

Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook

Until 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens and taxanes. This article explores the current and future outlooks for combination therapy with IOs in urothelial carcinoma.


Reem Akel, MD

Latest:

Cross Q&A: The Memorial Sloan-Kettering Mavericks

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.


Helga Maria Alessandra Lipari, MD

Latest:

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy

A survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.


Peter Mallmann, MD

Latest:

Emergency Fertility Preservation in a Young Woman With Non-Hodgkin Lymphoma

A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.


Ronan J. Kelly, MD

Latest:

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.


Brian Hinds, MD

Latest:

Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma

In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.


Tiffany Richards, PhD, ANP-BC, AOCNP

Latest:

Bispecific Selection in BCMA-failed Therapy for Relapsed Refractory Multiple Myeloma

Panelists discuss how to select appropriate bispecific antibody therapies for patients with relapsed/refractory multiple myeloma who have failed BCMA-targeted treatments, considering factors such as alternative targets, mechanisms of resistance, and emerging clinical data to provide effective subsequent treatment options.


Alexey Danilov, MD, PhD

Latest:

Unmet Needs and Future Perspectives in the Treatment of CLL

The panel shares some final thoughts on unmet needs and the future of CLL treatment.



Eric J. Sherman, MD

Latest:

Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid Cancer

Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.




Süheyla Aytaç Arslan, MD

Latest:

Spinal ATRT and Radiotherapy Case Report in an Adult Man

A rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.




Timothy Schmidt, MD

Latest:

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.


Pallawi Torka, MD

Latest:

Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Pallawi Torka, MD, and the Oncology Brothers discuss the therapeutic landscape for patients with relapsed/refractory mantle cell lymphoma.


Christine M. Eischen, PhD

Latest:

Studying Anti-MDM2 PROTAC May Yield New Modality in p53-Mutated Cancer

Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.


Deanna Griffie, MSN, AGNP-BC

Latest:

Unmet Needs in Patient Care for Metastatic Colorectal Cancer

The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.